These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 22517688)

  • 1. Clinical and pathological response to induction chemotherapy used as a prognostic factor in inflammatory breast cancer. Single institution experience.
    Kolarevic D; Tomasevic Z; Dzodic R; Gavrilovic D; Zegarac M
    J BUON; 2012; 17(1):21-6. PubMed ID: 22517688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
    Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does response to induction chemotherapy predict survival for locally advanced non-small-cell lung cancer? Secondary analysis of RTOG 8804/8808.
    McAleer MF; Moughan J; Byhardt RW; Cox JD; Sause WT; Komaki R
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):802-8. PubMed ID: 19540055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Locally advanced non inflammatory breast cancer treated by combined chemotherapy and preoperative irradiation: updated results in a series of 120 patients].
    Lerouge D; Touboul E; Lefranc JP; Genestie C; Moureau-Zabotto L; Blondon J
    Cancer Radiother; 2004 Jun; 8(3):155-67. PubMed ID: 15217583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer and neoadjuvant therapy: any predictive marker?
    Vyzula R; Dusek L; Zaloudík J; Demlová R; Klimes D; Selvekerová S
    Neoplasma; 2004; 51(6):471-80. PubMed ID: 15640958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma.
    Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA
    Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy.
    Gonzalez-Angulo AM; McGuire SE; Buchholz TA; Tucker SL; Kuerer HM; Rouzier R; Kau SW; Huang EH; Morandi P; Ocana A; Cristofanilli M; Valero V; Buzdar AU; Hortobagyi GN
    J Clin Oncol; 2005 Oct; 23(28):7098-104. PubMed ID: 16192593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
    Radosavljevic D; Golubicic I; Gavrilovic D; Kezic I; Jelic S
    J BUON; 2009; 14(2):203-9. PubMed ID: 19650167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of initial clinical disease stage after achieving pathological complete response.
    Dawood S; Broglio K; Kau SW; Islam R; Symmans WF; Buchholz TA; McGuire SE; Meric-Bernstam F; Cristofanilli M; Hortobágyi GN; Gonzalez-Angulo AM
    Oncologist; 2008 Jan; 13(1):6-15. PubMed ID: 18245008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
    Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
    J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcomes in stage IIIB breast cancer patients who achieved less than a pathological complete response (Ionta MT; Atzori F; Deidda MC; Pusceddu V; Palmeri S; Frau B; Murgia M; Barca M; Minerba L; Massidda B
    Oncologist; 2009 Nov; 14(11):1051-60. PubMed ID: 19897535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial response to chemotherapy, not delay in diagnosis, predicts overall survival in inflammatory breast cancer cases.
    Hoffman HJ; Khan A; Ajmera KM; Zolfaghari L; Schenfeld JR; Levine PH
    Am J Clin Oncol; 2014 Aug; 37(4):315-21. PubMed ID: 23241503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multivariate analysis of survival in inflammatory breast cancer: impact of intensity of chemotherapy in multimodality treatment.
    Bertucci F; Tarpin C; Charafe-Jauffret E; Bardou VJ; Braud AC; Tallet A; Gravis G; Viret F; Gonçalves A; Houvenaeghel G; Blaise D; Jacquemier J; Maraninchi D; Viens P
    Bone Marrow Transplant; 2004 May; 33(9):913-20. PubMed ID: 15004544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor heparanase expression in predicting response to induction chemotherapy in patients with locally advanced laryngeal cancer.
    Dincer M; Altundag K; Cengiz M; Ozyar E; Sungur A; Hosal S; Gullu IH
    J BUON; 2012; 17(2):337-42. PubMed ID: 22740215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can response to induction chemotherapy be a predictive marker for ultimate outcome in hypopharyngeal cancer?
    Han MW; Ryu IS; Lee SW; Kim SB; Roh JL; Choi SH; Kim SY; Nam SY
    Otolaryngol Head Neck Surg; 2012 Jan; 146(1):74-80. PubMed ID: 21896788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exclusive alternating chemotherapy and radiotherapy in nonmetastatic inflammatory breast cancer: 20 years of follow-up.
    Bourgier C; Pessoa EL; Dunant A; Heymann S; Spielmann M; Uzan C; Mathieu MC; Arriagada R; Marsiglia H
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):690-5. PubMed ID: 21277101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of local and distant disease relapse in patients with breast cancer treated with primary chemotherapy: do patients with a complete pathological response differ from those with residual tumour in the breast?
    Chaturvedi S; McLaren C; Schofield AC; Ogston KN; Sarkar TK; Hutcheon AW; Miller ID; Heys SD
    Breast Cancer Res Treat; 2005 Sep; 93(2):151-8. PubMed ID: 16187235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study.
    Franciosi V; Cocconi G; Michiara M; Di Costanzo F; Fosser V; Tonato M; Carlini P; Boni C; Di Sarra S
    Cancer; 1999 Apr; 85(7):1599-605. PubMed ID: 10193952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer.
    Swain SM; Sorace RA; Bagley CS; Danforth DN; Bader J; Wesley MN; Steinberg SM; Lippman ME
    Cancer Res; 1987 Jul; 47(14):3889-94. PubMed ID: 3036348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer.
    Burcombe R; Wilson GD; Dowsett M; Khan I; Richman PI; Daley F; Detre S; Makris A
    Breast Cancer Res; 2006; 8(3):R31. PubMed ID: 16790076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.